Introduction
Methods
Literature Search
Study Selection and Data Extraction
Statistical Analyses
Results
Characteristics and Methodological Quality of Included Studies
First author, year | Study duration | Treatment groups | No. of patients | Age (years) | Male (%) | Body mass index (kg/m2) | Duration of diabetes mellitus (years) | Baseline glycated hemoglobin (HbA1c) (%) | Baseline weight (kg) |
---|---|---|---|---|---|---|---|---|---|
DPP-4 inhibitors + metformin initial combination therapy vs. metformin monotherapy | |||||||||
Goldstein, 2007 [13] | 24 weeks | Sitagliptin 50 mg + metformin 1000 mg bid | 182 | 53.3 ± 9.6 | 42.3 | 32.4 ± 6.6 | 4.4 ± 4.2 | 8.7 ± 0.9 | – |
Metformin 1000 mg bid | 182 | 53.2 ± 9.6 | 45.1 | 32.2 ± 7.1 | 4.4 ± 4.4 | 8.7 ± 0.9 | – | ||
Goldstein, 2007-2 [13] | 24 weeks | Sitagliptin 50 mg + metformin 500 mg bid | 190 | 54.1 ± 10.0 | 55.3 | 32.1 ± 6.7 | 4.5 ± 4.7 | 8.8 ± 1.0 | – |
Metformmin 500 mg bid | 182 | 53.2 ± 10.2 | 48.9 | 32.1 ± 6.8 | 4.5 ± 3.9 | 8.9 ± 1.0 | – | ||
Bosi, 2009 [14] | 24 weeks | Vildagliptin 50 mg + metformin 1000 mg bid | 295 | 52.8 ± 10.64 | 58 | 31.37 ± 4.75 | 1.87 ± 2.60 | 8.70 ± 1.03 | 89.79 ± 18.87 |
Metformin 1000 mg bid | 294 | 52.4 ± 10.71 | 58.2 | 31.31 ± 4.58 | 2.19 ± 3.33 | 8.62 ± 0.93 | 88.43 ± 17.39 | ||
Jadzinsky, 2009 [15] | 24 weeks | Saxagliptin 10 mg + metformin | 323 | 52.1 ± 11.6 | 45.2 | 30.3 ± 5.0 | 1.4 ± 2.5 | 9.5 ± 1.2 | 82.5 ± 16.9 |
Metformin | 328 | 51.8 ± 10.7 | 49.7 | 30.2 ± 4.9 | 1.7 ± 3.1 | 9.4 ± 1.3 | 82.8 ± 17.5 | ||
Reasner, 2011 [16] | 18 weeks | Sitagliptin/metformin FDC | 625 | 49.4 ± 10.5 | 56 | 32.9 ± 7.2 | 3.5 ± 4.5 | 9.9 ± 1.8 | 94.7 ± 23.4 |
Metformmin | 621 | 50.0 ± 10.5 | 57 | 33.7 ± 7.8 | 3.2 ± 4.3 | 9.8 ± 1.8 | 97.2 ± 25.5 | ||
Haak, 2012 [17] | 24 weeks | Linagliptin 2.5 mg + metformin 1000 mg bid | 143 | 56.4 ± 10.7 | 53.8 | 28.6 ± 4.8 | – | 8.7 ± 1.0 | 76.7 ± 16.0 |
Metformin 1000 mg bid | 147 | 55.2 ± 10.6 | 53.1 | 29.5 ± 5.3 | – | 8.5 ± 0.9 | 80.0 ± 18.5 | ||
Haak, 2012-2 [17] | 24 weeks | Linagliptin 2.5 mg + metformin 500 mg bid | 143 | 55.6 ± 11.2 | 51.0 | 29.7 ± 5.3 | – | 8.7 ± 1.0 | 80.8 ± 19.0 |
Metformin 500 mg bid | 144 | 52.9 ± 10.4 | 56.9 | 28.9 ± 4.8 | – | 8.7 ± 0.9 | 79.9 ± 18.4 | ||
Pratley, 2014 [18] | 26 weeks | Alogliptin/metformin 12.5/1000 mg bid | 114 | 54.6 ± 10.42 | 54.4 | 31.0 ± 5.38 | 4.2 ± 4.97 | – | – |
Metformin 1000 mg bid | 111 | 52.6 ± 11.30 | 45.9 | 30.5 ± 5.0 | 4.1 ± 4.59 | – | – | ||
Pratley, 2014-2 [18] | 26 weeks | Alogliptin/metformin 12.5/500 mg bid | 111 | 53.7 ± 11.59 | 43.2 | 30.9 ± 5.35 | 4.1 ± 4.78 | – | – |
Metformin 500 mg bid | 114 | 54.6 ± 10.20 | 41.2 | 30.2 ± 4.84 | 3.8 ± 3.90 | – | – | ||
Ji, 2015 [19] | 24 weeks | Linagliptin 5 mg + metformin 1000 mg | 344 | 53.1 ± 10.7 | 49.1 | 29 ± 5.7 | – | 8 ± 1.0 | 76.7 ± 18.8 |
Metformin 2000 mg | 345 | 52.9 ± 10.7 | 45.8 | 29 ± 5.6 | – | 8 ± 0.8 | 76.0 ± 18.8 | ||
Ji, 2016 [20] | 24 weeks | Sitagliptin 50 mg/metformin 850 mg bid | 125 | 52.4 ± 9.3 | 53.6 | 25.4 ± 3.1 | 1.1 ± 0.3 | 8.6 ± 0.9 | 69.4 ± 10.8 |
Metformin 850 mg bid | 124 | 53.0 ± 10.3 | 60.5 | 25.8 ± 3.5 | 1.1 ± 0.2 | 8.7 ± 1.1 | 71.1 ± 11.8 | ||
Ji, 2016-2 [20] | 24 weeks | Sitagliptin 50 mg/metformin 500 mg bid | 122 | 52.6 ± 11.3 | 69.7 | 26.1 ± 3.4 | 1.1 ± 0.3 | 8.5 ± 1.0 | 72.4 ± 12.1 |
Metformin 500 mg bid | 126 | 52.6 ± 9.5 | 54.8 | 26.0 ± 3.7 | 1.0 ± 0.2 | 8.7 ± 1.0 | 71.1 ± 13.7 | ||
Mu, 2016 [21] | 24 weeks | Linagliptin 2.5 mg/metformin 1000 mg bid | 147 | 50.7 ± 9.4 | 59.2 | 26.0 ± 3.7 | – | 8.7 ± 1.0 | 70.5 ± 12 |
Metformin 1000 mg bid | 144 | 51.4 ± 10.4 | 63.2 | 26.1 ± 3.3 | – | 8.6 ± 1.0 | 71.0 ± 12 | ||
Mu, 2016-2 [21] | 24 weeks | Linagliptin 2.5 mg/metformin 500 mg bid | 147 | 51.4 ± 10.2 | 62.6 | 26.0 ± 3.6 | – | 8.7 ± 0.9 | 70.8 ± 12 |
Metformin 500 mg bid | 145 | 52.1 ± 9.6 | 62.8 | 25.8 ± 3.3 | – | 8.7 ± 1.1 | 69.1 ± 10.7 | ||
Dou, 2017 [22] | 24 weeks | Saxagliptin 5 mg + metformin 500 mg | 210 | 50.8 ± 10.4 | 64.8 | 26.7 ± 3.7 | 0.97 ± 2.1 | 9.4 ± 1.1 | – |
Metformin 500 mg + placebo | 207 | 50.1 ± 11.0 | 63.8 | 26.5 ± 3.6 | 0.72 ± 2.1 | 9.5 ± 1.0 | – | ||
JI, 2017 [23] | 26 weeks | Alogliptin 12.5 mg + metformin 500 mg FDC bid | 159 | 53.4 ± 10.46 | 57.2 | 26.16 ± 3.51 | – | 8.39 ± 0.81 | – |
Metformin 500 mg bid | 162 | 53.6 ± 9.91 | 50.6 | 26.30 ± 3.57 | – | 8.40 ± 0.78 | – | ||
DPP-4 inhibitors + metformin initial combination therapy vs. DPP-4 inhibitor monotherapy | |||||||||
Goldstein, 2007 [13] | 24 weeks | Sitagliptin 50 mg + metformin 1000 mg bid | 182 | 53.3 ± 9.6 | 42.3 | 32.4 ± 6.6 | 4.4 ± 4.2 | 8.7 ± 0.9 | – |
Sitagliptin 100 mg qd | 179 | 53.3 ± 10.2 | 52.0 | 31.2 ± 5.9 | 4.4 ± 4.6 | 8.9 ± 1.0 | – | ||
Bosi, 2009 [14] | 24 weeks | Vildagliptin 50 mg + metformin 1000 mg bid | 295 | 52.8 ± 10.64 | 58 | 31.37 ± 4.75 | 1.87 ± 2.60 | 8.70 ± 1.03 | 89.79 ± 18.87 |
Vildagliptin 50 mg bid | 300 | 53.5 ± 10.95 | 60 | 31.26 ± 4.82 | 2.12 ± 3.32 | 8.68 ± 1.02 | 87.84 ± 17.93 | ||
Jadzinsky, 2009 [15] | 24 weeks | Saxagliptin 10 mg + metformin | 323 | 52.1 ± 11.6 | 45.2 | 30.3 ± 5.0 | 1.4 ± 2.5 | 9.5 ± 1.2 | 82.5 ± 16.9 |
Saxagliptin 10 mg | 335 | 52.1 ± 10.2 | 50.4 | 30.2 ± 4.9 | 1.7 ± 2.8 | 9.6 ± 1.3 | 83.1 ± 16.9 | ||
Haak, 2012 [17] | 24 weeks | Linagliptin 2.5 mg + metformin 1000 mg bid | 143 | 56.4 ± 10.7 | 53.8 | 28.6 ± 4.8 | – | 8.7 ± 1.0 | 76.7 ± 16.0 |
Linagliptin 5 mg qd | 142 | 56.2 ± 10.8 | 56.3 | 29.0 ± 4.7 | – | 8.7 ± 1.0 | 79.1 ± 17.3 | ||
Pratley, 2014 [18] | 26 weeks | Alogliptin/metformin 12.5/1000 mg bid | 114 | 54.6 ± 10.42 | 54.4 | 31.0 ± 5.38 | 4.2 ± 4.97 | – | – |
Alogliptin 25 mg qd | 112 | 52.6 ± 9.38 | 42.9 | 30.8 ± 5.22 | 3.6 ± 4.12 | – | – | ||
Ross, 2015 [24] | 24 weeks | Linagliptin 5 mg + metformin | 159 | 49 ± 10.9 | 43.4 | 29.84 ± 5.82 | – | 9.79 ± 1.19 | – |
Linagliptin 5 mg | 157 | 48.6 ± 11.2 | 49 | 29.63 ± 5.43 | – | 9.88 ± 1.10 | – | ||
Ji, 2016 [20] | 24 weeks | Sitagliptin 50 mg/metformin 850 mg bid | 125 | 52.4 ± 9.3 | 53.6 | 25.4 ± 3.1 | 1.1 ± 0.3 | 8.6 ± 0.9 | 69.4 ± 10.8 |
Sitagliptin 50 mg bid | 120 | 51.7 ± 10.2 | 61.7 | 26.0 ± 3.5 | 1.1 ± 0.2 | 8.7 ± 1.1 | 71.8 ± 12.1 | ||
Mu, 2016 [21] | 24 weeks | Linagliptin 2.5 mg/metformin 1000 mg bid | 147 | 50.7 ± 9.4 | 59.2 | 26.0 ± 3.7 | – | 8.7 ± 1.0 | 70.5 ± 12 |
Linagliptin 5 mg qd | 147 | 50.8 ± 10.5 | 51.7 | 26.2 ± 3.9 | – | 8.7 ± 0.9 | 70.2 ± 13.5 | ||
Dou, 2017 [22] | 24 weeks | Saxagliptin 5 mg + metformin 500 mg | 210 | 50.8 ± 10.4 | 64.8 | 26.7 ± 3.7 | 0.97 ± 2.1 | 9.4 ± 1.1 | – |
Saxagliptin 5 mg + placebo | 213 | 49.5 ± 10.9 | 70.9 | 26.5 ± 3.2 | 0.73 ± 1.6 | 9.4 ± 1.0 | – | ||
JI, 2017 [23] | 26 weeks | Alogliptin 12.5 mg + metformin 500 mg FDC bid | 159 | 53.4 ± 10.46 | 57.2 | 26.16 ± 3.51 | – | 8.39 ± 0.81 | – |
Alogliptin 12.5 mg bid | 163 | 55.4 ± 9.62 | 60.1 | 26.16 ± 3.92 | – | 8.48 ± 0.71 | – | ||
SU + metformin initial combination therapy vs. metformin monotherapy | |||||||||
Garber, 2002 [25] | 20 weeks | Glyburide/metformin 2.5/500 mg | 165 | 58.1 ± 9.8 | 58.2 | 29.6 ± 4.5 | 3.30 ± 3.18 | 8.18 ± 1.14 | 86.7 ± 17.5 |
Metformin 500 mg | 161 | 56.0 ± 11.0 | 57.8 | 30.4 ± 4.3 | 2.98 ± 2.74 | 8.26 ± 1.08 | 88.6 ± 14.9 | ||
Garber, 2003 [26] | 16 weeks | Glyburide/metformin 1.25/500 mg | 171 | 55.6 ± 11.2 | 44.4 | 31.4 ± 4.6 | 3.0 ± 3.0 | 8.8 ± 1.5 | 91.9 ± 17.4 |
Metformin 500 mg | 164 | 54.7 ± 11.8 | 43.3 | 31.4 ± 4.0 | 2.6 ± 2.3 | 8.5 ± 1.4 | 92.8 ± 15.6 | ||
Horton, 2004 [27] | 24 weeks | Nateglinide 120 mg + metformin 500 mg tid | 89 | 57.7 ± 1.2 | 65.2 | 30.6 ± 0.4 | 3.4 ± 0.4 | 8.2 ± 0.1 | – |
Metformin 500 mg tid | 104 | 55.4 ± 1.1 | 67.3 | 29.9 ± 0.4 | 3.7 ± 0.4 | 8.3 ± 0.1 | – | ||
SU/glinide + metformin initial combination therapy vs. SU/glinide monotherapy | |||||||||
Garber, 2002 [25] | 20 weeks | Glyburide/metformin 2.5/500 mg | 165 | 58.1 ± 9.8 | 58.2 | 29.6 ± 4.5 | 3.30 ± 3.18 | 8.18 ± 1.14 | 86.7 ± 17.5 |
Glyburide 2.5 mg | 161 | 56.5 ± 10.5 | 50.9 | 30.3 ± 3.9 | 2.81 ± 3.14 | 8.21 ± 1.09 | 87.2 ± 15.3 | ||
Garber, 2003 [26] | 16 weeks | Glyburide/metformin 1.25/500 mg | 171 | 55.6 ± 11.2 | 44.4 | 31.4 ± 4.6 | 3.0 ± 3.0 | 8.8 ± 1.5 | 91.9 ± 17.4 |
Glyburide 2.5 mg | 151 | 55.3 ± 12.2 | 43.7 | 31.1 ± 4.3 | 3.0 ± 2.6 | 8.7 ± 1.4 | 91.0 ± 16.0 | ||
Horton, 2004 [27] | 24 weeks | Nateglinide 120 mg +Metformin 500 mg tid | 89 | 57.7 ± 1.2 | 65.2 | 30.6 ± 0.4 | 3.4 ± 0.4 | 8.2 ± 0.1 | – |
Nateglinide 120 mg | 104 | 57.9 ± 1.0 | 56.7 | 29.9 ± 0.4 | 4.7 ± 0.6 | 8.1 ± 0.1 | – | ||
TZD + metformin initial combination therapy vs. metformin monotherapy | |||||||||
Rosenstock, 2006 [28] | 32 weeks | Rosiglitazone/Metformmin | 155 | 50.1 ± 10.7 | 57 | 33.2 ± 7.7 | 2.3 ± 2.7 | 8.9 ± 1.1 | – |
Metformin | 154 | 51.5 ± 10.4 | 56 | 32.5 ± 7.0 | 2.9 ± 3.7 | 8.8 ± 1.0 | – | ||
Stewart, 2006 [29] | 32 weeks | Roziglitazone + metformin | 254 | 58.9 ± 8.4 | 55 | 30.9 ± 5.4 | 3.7 ± 3.6 | 7.2 ± 0.6 | 88.1 ± 16.3 |
metformin | 272 | 59.0 ± 7.9 | 56 | 30.6 ± 5.5 | 3.7 ± 3.6 | 7.2 ± 0.6 | 87.2 ± 16.5 | ||
Perez, 2009 [30] | 24 weeks | Pioglitazone 15 mg + metformin 850 mg bid | 201 | 54.7 ± 12.2 | 44.8 | 30.8 ± 5.7 | – | 8.89 ± 0.07 | – |
Metformin 850 mg bid | 210 | 53.7 ± 12.0 | 46.7 | 30.8 ± 5.7 | – | 8.65 ± 0.07 | – | ||
Borges, 2011 [31] | 80 weeks | Rosiglitazone/metformin | 344 | 51.5 ± 10.5 | 53 | 32.2 ± 6.8 | 2.3 ± 3.1 | 8.6 ± 0.9 | 87.1 ± 21.3 |
Metformin | 334 | 50.7 ± 10.5 | 53 | 33.1 ± 7.1 | 2.6 ± 3.3 | 8.6 ± 0.9 | 90.6 ± 22.8 | ||
TZD + metformin initial combination therapy vs. TZD monotherapy | |||||||||
Rosenstock, 2006 [28] | 32 weeks | Rosiglitazone/Metformmin | 155 | 50.1 ± 10.7 | 57 | 33.2 ± 7.7 | 2.3 ± 2.7 | 8.9 ± 1.1 | – |
Rosiglitazone | 159 | 50.6 ± 10.2 | 58 | 32.8 ± 7.1 | 2.7 ± 3.0 | 8.8 ± 1.0 | – | ||
Perez, 2009 [30] | 24 weeks | Pioglitazone 15 mg + metformin 850 mg bid | 201 | 54.7 ± 12.2 | 44.8 | 30.8 ± 5.7 | – | 8.89 ± 0.07 | – |
Pioglitazone 15 mg bid | 189 | 54.0 ± 12.1 | 34.9 | 31.2 ± 5.5 | – | 8.69 ± 0.07 | – | ||
SGLT2 inhibitors + metformin initial combination therapy vs. metformin monotherapy | |||||||||
Henry, 2012–2 [32] | 24 weeks | Dapagliflozin 10 mg + metformin 2000 mg | 211 | 51.0 ± 10.1 | 50.2 | – | 2.2 ± 3.3 | 9.1 ± 1.3 | 88.4 ± 19.7 |
Metformin 2000 mg + placebo | 208 | 52.7 ± 10.4 | 46.6 | – | 1.9 ± 4.0 | 9.1 ± 1.3 | 87.2 ± 19.4 | ||
Hadjadj, 2016 [33] | 24 weeks | Empagliflozin 25 mg + metformin 2000 mg | 169 | 53.6 ± 10.7 | 52.1 | 30.4 ± 5.3 | – | 8.66 ± 1.14 | 83.8 ± 19.8 |
Metformin 2000 mg | 164 | 51.6 ± 10.8 | 56.1 | 30.5 ± 5.9 | – | 8.58 ± 1.13 | 83.7 ± 20.1 | ||
Rosenstock, 2016 [34] | 26 weeks | Canagliflozin 300/Metformin 2000 mg | 237 | 55.4 ± 9.8 | 48.5 | 32.8 ± 6.5 | 3.3 ± 3.9 | 8.9 ± 1.2 | 91.4 ± 21.4 |
Metformin 2000 mg | 237 | 55.2 ± 9.8 | 48.9 | 33.0 ± 6.0 | 3.3 ± 4.5 | 8.8 ± 1.2 | 92.1 ± 20.1 | ||
SGLT2 inhibitors + metformin initial combination therapy vs. SGLT2 inhibitor monotherapy | |||||||||
Henry, 2012–1 [32] | 24 weeks | Dapagliflozin 5 mg + metformin | 194 | 51.7 ± 9.3 | 40.2 | – | 1.6 ± 2.4 | 9.2 ± 1.3 | 84.1 ± 19.5 |
Dapagliflozin 5 mg + placebo | 203 | 52.3 ± 10.2 | 45.3 | – | 1.6 ± 3.1 | 9.1 ± 1.4 | 86.2 ± 21.1 | ||
Henry, 2012–2 [32] | 24 weeks | Dapagliflozin 10 mg + metformin | 211 | 51.0 ± 10.1 | 50.2 | – | 2.2 ± 3.3 | 9.1 ± 1.3 | 88.4 ± 19.7 |
Dapaglifozin 10 mg + placebo | 219 | 51.1 ± 11.5 | 47.9 | – | 2.1 ± 3.8 | 9.1 ± 1.3 | 88.5 ± 19.3 | ||
Hadjadj, 2016 [33] | 24 weeks | Empagliflozin 25 mg + metformin 2000 mg | 169 | 53.6 ± 10.7 | 52.1 | 30.4 ± 5.3 | – | 8.66 ± 1.14 | 83.8 ± 19.8 |
Empagliflozin 25 mg | 164 | 53.3 ± 10.7 | 50.6 | 30.6 ± 5.9 | – | 8.86 ± 1.29 | 83.1 ± 20.3 | ||
Hadjadj, 2016-2 [33] | 24 weeks | Empagliflozin 10 mg + metformin 2000 mg | 167 | 52.3 ± 11.3 | 59.3 | 30.5 ± 5.0 | – | 8.65 ± 1.23 | 83.0 ± 19.1 |
Empagliflozin 10 mg | 169 | 53.1 ± 10.7 | 57.4 | 30.3 ± 5.2 | – | 8.62 ± 1.24 | 83.8 ± 19.8 | ||
Rosenstock, 2016 [34] | 26 weeks | Canagliflozin 100 mg/Metformin | 237 | 54.2 ± 9.6 | 45.6 | 31.9 ± 5.3 | 2.9 ± 3.3 | 8.8 ± 1.1 | 88.3 ± 17.6 |
Canagliflozin 100 mg | 237 | 54.0 ± 10.7 | 44.3 | 32.4 ± 5.4 | 3.5 ± 4.4 | 8.8 ± 1.2 | 90.2 ± 18.6 | ||
Rosenstock, 2016-2 [34] | 26 weeks | Canagliflozin 300/Metformin | 237 | 55.4 ± 9.8 | 48.5 | 32.8 ± 6.5 | 3.3 ± 3.9 | 8.9 ± 1.2 | 91.4 ± 21.4 |
Canagliflozin 300 mg | 238 | 55.8 ± 9.6 | 52.5 | 32.6 ± 5.8 | 3.3 ± 4.4 | 8.8 ± 1.2 | 93.0 ± 19.9 | ||
DPP-4 inhibitors + TZD initial combination therapy vs. TZD monotherapy | |||||||||
Rosenstock, 2007 [35] | 24 weeks | Vildagliptin + piogglitazone 100/30 mg qd | 148 | 51.0 ± 11.3 | 58.1 | 29.6 ± 5.8 | 2.0 ± 3.1 | 8.8 ± 1.1 | – |
Piogglitazone 30 mg qd | 161 | 52.4 ± 10.3 | 64.0 | 28.9 ± 5.5 | 2.2 ± 3.3 | 8.7 ± 1.0 | – | ||
Rosenstock, 2010 [36] | 26 weeks | Alogliptin 25 mg + piogglitazone 30 mg | 164 | – | – | – | – | 8.80 ± 0.962 | – |
Pioglitazone 30 mg | 163 | – | – | – | – | 8.76 ± 1.005 | – | ||
Yoon, 2011 [37] | 24 weeks | Sitagliptin 100 mg + piogglitazone 30 mg | 261 | 50.2 ± 10.2 | 52.5 | 29.7 ± 5.1 | 2.6 ± 4.3 | 9.5 ± 1.2 | 80.1 ± 17.4 |
Piogglitazone 30 mg | 259 | 51.7 ± 11.2 | 56.0 | 29.6 ± 5.2 | 2.1 ± 3.9 | 9.5 ± 1.2 | 80.4 ± 17.8 | ||
Yoon, 2012 [38] | 54 weeks | Sitagliptin 100 mg + piogglitazone 45 mg | 164 | 51.4 ± 10.0 | 52.4 | 29.7 ± 4.8 | 2.6 ± 4.0 | 9.4 ± 1.1 | 81.6 ± 17.4 |
Piogglitazone 45 mg | 153 | 52.3 ± 11.5 | 58.8 | 29.9 ± 5.3 | 1.6 ± 3.7 | 9.4 ± 1.4 | 81.9 ± 18.4 | ||
Gomis, 2011 [39] | 24 weeks | Linagliptin 5 mg + pioglitazone 30 mg | 259 | 57.7 ± 9.6 | 58.7 | 28.7 ± 4.8 | – | 8.60 ± 0.79 | 78.3 ± 15.6 |
Pioglitazone 30 mg + placebo | 130 | 57.1 ± 10.1 | 65.4 | 29.7 ± 4.8 | – | 8.58 ± 0.87 | 82.7 ± 15.8 | ||
Henry, 2014 [40] | 54 weeks | Sitagliptin 100 mg + pioglitazone 15 mg | 193 | 52.6 | 50.8 | 30.7 ± 5.4 | 4.1 ± 4 | 8.9 ± 1.2 | – |
Pioglitazone 15 mg | 183 | 50.3 | 65 | 30.7 ± 5.2 | 3.7 ± 4.2 | 8.9 ± 1.0 | – | ||
Henry, 2014–2 [40] | 54 weeks | Sitagliptin 100 mg + pioglitazone 30 mg | 190 | 51.1 | 58.9 | 31.1 ± 5.8 | 3.8 ± 3.8 | 8.7 ± 1.1 | – |
Pioglitazone 30 mg | 194 | 51.8 | 54.1 | 30.9 ± 5.6 | 3.9 ± 4.0 | 8.9 ± 1.1 | – | ||
Henry, 2014–3 [40] | 54 weeks | Sitagliptin 100 mg + pioglitazone 45 mg | 198 | 53.5 | 59.6 | 30.5 ± 4.9 | 4.0 ± 4.5 | 8.9 ± 1.1 | – |
Pioglitazone 45 mg | 188 | 52.5 | 50.5 | 31.2 ± 5.1 | 3.7 ± 4.0 | 8.8 ± 1.1 | – | ||
DPP-4 inhibitors + TZD initial combination therapy vs. DPP-4 inhibitor monotherapy | |||||||||
Henry, 2014 [40] | 54 weeks | Sitagliptin 100 mg + pio 30 mg | 190 | 51.1 | 58.9 | 31.1 ± 5.8 | 3.8 ± 3.8 | 8.7 ± 1.1 | – |
Sitagliptin 100 mg | 186 | 51 | 60.2 | 31.4 ± 5.7 | 4.5 ± 6.8 | 8.7 ± 1.2 | – | ||
Rosenstock, 2007 [35] | 24 weeks | Vildagliptin + piog 100/30 mg qd | 148 | 51.0 ± 11.3 | 58.1 | 29.6 ± 5.8 | 2.0 ± 3.1 | 8.8 ± 1.1 | – |
Vildagliptin 100 mg qd | 154 | 51.4 ± 10.8 | 63.6 | 29.4 ± 5.8 | 1.9 ± 3.1 | 8.6 ± 1.0 | – | ||
Rosenstock, 2010 [36] | 26 weeks | Alogliptin 25 mg + piogglitazone 30 mg | 164 | – | – | – | – | 8.80 ± 0.962 | – |
Alogliptin 25 mg | 164 | – | – | – | – | 8.80 ± 0.988 | – | ||
SU/glinide + AGI initial combination therapy vs. AGI monotherapy | |||||||||
Tatsumi, 2013 [41] | 12 weeks | Miglitol + mitiglinide | 21 | 63.4 ± 8.9 | 47.6 | 24.8 ± 0.9 | 7.6 ± 5.5 | 7.19 ± 0.50 | 62.2 ± 2.9 |
Miglitol | 22 | 62.9 ± 11.4 | 68.2 | 24.9 ± 1.2 | 7.3 ± 9.3 | 7.09 ± 0.82 | 67.7 ± 3.4 | ||
SU/glinide + AGI initial combination therapy vs. SU/glinide monotherapy | |||||||||
Tatsumi, 2013 [41] | 12 weeks | Miglitol + mitiglinide | 21 | 63.4 ± 8.9 | 47.6 | 24.8 ± 0.9 | 7.6 ± 5.5 | 7.19 ± 0.50 | 62.2 ± 2.9 |
Mitiglinide | 21 | 65.4 ± 10.4 | 42.9 | 25.2 ± 0.8 | 6.1 ± 6.2 | 7.10 ± 0.48 | 62.7 ± 2.5 | ||
SU/glinide + TZD initial combination therapy vs. TZD monotherapy | |||||||||
Chou, 2008 [42] | 28 weeks | Rosiglitazone + glimepiride (8 mg/4 mg) | 218 | 54.9 ± 11.6 | 59.6 | 31.8 ± 6.2 | 2.0 ± 0.30 | 9.2 ± 1.3 | 90.2 ± 19.7 |
Rosiglitazone | 230 | 53.6 ± 10.7 | 60.0 | 31.3 ± 5.8 | 2.0 ± 0.21 | 9.1 ± 1.3 | 88.9 ± 19.8 | ||
SU/glinide + TZD initial combination therapy vs. SU/glinide monotherapy | |||||||||
Chou, 2008 [42] | 28 weeks | Rosiglitazone + glimepiride (8 mg/4 mg) | 218 | 54.9 ± 11.6 | 59.6 | 31.8 ± 6.2 | 2.0 ± 0.30 | 9.2 ± 1.3 | 90.2 ± 19.7 |
Glimepiride | 222 | 53.0 ± 11.0 | 57.7 | 31.8 ± 7.2 | 1.0 ± 0.18 | 9.0 ± 1.3 | 91.6 ± 23.6 | ||
DPP-4 inhibitors + metformin initial combination therapy vs. TZD monotherapy | |||||||||
Wainstein, 2012 [43] | 32 weeks | Sitagliptin + metformin | 261 | 52.4 ± 10.7 | 54.8 | 30.0 ± 6.1 | 3.2 ± 4.0 | 9.0 ± 1.3 | 82.8 ± 21.1 |
Pioglitazone | 256 | 52.2 ± 11.0 | 52.3 | 29.6 ± 5.5 | 3.3 ± 3.5 | 8.9 ± 1.3 | 81.4 ± 19.9 | ||
DPP-4 inhibitors + metformin initial combination therapy vs SU monotherapy | |||||||||
Amblee, 2016 [44] | 12 weeks | Saxagliptin + metformin FDC | 50 | 45.6 ± 7.3 | 80 | 34.3 ± 11.3 | – | 10.9 ± 1.4 | – |
Glipizide | 50 | 43.2 ± 10.6 | 82 | 34.3 ± 5.8 | – | 11.1 ± 1.39 | – | ||
Colesvelam + metformin initial combination therapy vs. metformin monotherapy | |||||||||
Rosenstock, 2010 [45] | 16 weeks | Colesvelam + metformin | 145 | 52.7 ± 11.5 | 48 | 30.6 ± 4.7 | – | 7.8 ± 1.0 | 80.8 ± 15.5 |
Metformin | 141 | 53.9 ± 10.1 | 40 | 29.8 ± 4.4 | – | 7.5 ± 0.9 | 77.3 ± 16.2 | ||
DPP-4 inhibitors + AGI initial combination therapy vs AGI monotherapy | |||||||||
Mikada, 2014 [46] | 24 weeks | Miglitol + sitagliptin | 13 | 60.5 ± 11.5 | 53.8 | 28.3 ± 2.5 | 7.4 ± 3.1 | 7.14 ± 0.76 | 73.8 ± 10.2 |
Miglitol | 14 | 58.7 ± 7.0 | 78.6 | 29.5 ± 5.5 | 9.3 ± 5.8 | 6.90 ± 0.51 | 81.4 ± 11.2 | ||
DPP-4 inhibitors + AGI initial combination therapy vs. DPP-4 inhibitor monotherapy | |||||||||
Mikada, 2014 [46] | 24 weeks | Miglitol + sitagliptin | 13 | 60.5 ± 11.5 | 53.8 | 28.3 ± 2.5 | 7.4 ± 3.1 | 7.14 ± 0.76 | 73.8 ± 10.2 |
Sitagliptin | 14 | 59.2 ± 11.8 | 78.6 | 28.8 ± 2.5 | 7.6 ± 8.0 | 7.45 ± 0.93 | 76.8 ± 11.4 | ||
SGLT2 inhibitors + DPP-4 inhibitors initial combination therapy vs SGLT2 inhibitor monotherapy | |||||||||
Lewin 2015 [47] | 24 weeks | Empagliflozin 25 mg + linagliptin 5 mg | 134 | 54.2 ± 10.0 | 52.2 | 31.8 ± 5.3 | – | 7.99 ± 0.95 | 87.9 ± 18.2 |
Empagliflozin 25 mg | 133 | 56.0 ± 9.3 | 57.9 | 31.2 ± 5.7 | – | 7.99 ± 0.97 | 86.7 ± 19.7 | ||
SGLT2 inhibitors + DPP-4 inhibitors initial combination therapy vs. DPP-4 inhibitor monotherapy | |||||||||
Lewin 2015 [47] | 24 weeks | Empagliflozin 25 mg + linagliptin 5 mg | 134 | 54.2 ± 10.0 | 52.2 | 31.8 ± 5.3 | – | 7.99 ± 0.95 | 87.9 ± 18.2 |
Linagliptin 5 mg | 133 | 53.8 ± 11.5 | 56.4 | 31.9 ± 5.9 | – | 8.05 ± 0.89 | 89.5 ± 20.1 | ||
Triple initial combination therapy vs. conventional therapy | |||||||||
Abdul-Ghani, 2015 [48] | 24 months | Metformin + pioglitazone + exenatide | 79 | 47 ± 1 | 55 | 36.4 ± 1 | 0.42 ± 0.06 | 8.6 ± 0.2 | 101.6 ± 2.3 |
Conventional therapy | 91 | 46 ± 1 | 62 | 36.6 ± 1 | 0.42 ± 0.05 | 8.6 ± 0.2 | 101.0 ± 3.4 |
Efficacy of Initial Combination Therapy
Comparison group | Included studies | No. of patients | WMD | 95% CI | p value | I2 (%) | 95% CI of I2 |
---|---|---|---|---|---|---|---|
DPP-4 inhibitors + metformin vs. DPP-4 inhibitors | |||||||
HbA1c (%) | 10 | 1967/1951 | − 0.88 | − 0.99, − 0.78 | < 0.001 | 100 | 0.76, 1.24 |
FPG (mmol/l) | 9 | 1824/1823 | − 1.61 | − 1.84, − 1.37 | < 0.001 | 100 | 0.75, 1.25 |
PPG (mmol/l) | 6 | 1065/1020 | − 2.69 | − 3.27, − 2.12 | < 0.001 | 100 | 0.65, 1.35 |
Weight (kg) | 8 | 1627/1624 | − 1.00 | − 1.28, − 0.77 | < 0.001 | 100 | 0.73, 1.27 |
DPP-4 inhibitors + metformin vs. metformin | |||||||
HbA1c (%) | 11 | 3379/3375 | − 0.44 | − 0.57, − 0.31 | < 0.001 | 100 | 0.81, 1.19 |
FPG (mmol/l) | 10 | 3085/3086 | − 0.77 | − 1.02, − 0.51 | < 0.001 | 100 | 0.80, 1.20 |
PPG (mmol/l) | 5 | 1377/1374 | − 1.65 | − 2.09, − 1.21 | < 0.001 | 99 | 0.70, 1.28 |
Weight (kg) | 8 | 2505/2505 | 0.38 | 0.22, 0.54 | < 0.001 | 99 | 0.77, 1.21 |
SU/glinide + metformin vs. metformin | |||||||
HbA1c (%) | 3 | 425/429 | − 0.68 | − 0.86, − 0.50 | < 0.001 | 100 | 0.32, 1.68 |
FPG (mmol/l) | 3 | 425/429 | − 0.87 | − 1.38, − 0.36 | < 0.001 | 100 | 0.32, 1.68 |
PPG (mmol/l) | 3 | 425/429 | − 0.70 | − 1.02, − 0.38 | < 0.001 | 99 | 0.31, 1.67 |
Weight (kg) | 2 | 336/325 | 2.60 | 2.40, 2.80 | < 0.001 | 95 | – |
SU/glinide + metformin vs. SU/glinide | |||||||
HbA1c (%) | 3 | 425/416 | − 0.49 | − 0.77, − 0.20 | < 0.001 | 100 | 0.32, 1.68 |
FPG (mmol/l) | 3 | 425/416 | − 0.66 | − 1.12, − 0.20 | 0.005 | 100 | 0.32, 1.68 |
PPG (mmol/l) | 3 | 425/416 | − 0.87 | − 1.29, − 0.46 | < 0.001 | 100 | 0.32, 1.68 |
Weight (kg) | 2 | 336/312 | − 0.10 | − 0.69, 0.49 | 0.74 | 99 | – |
TZD + metformin vs. metformin | |||||||
HbA1c (%) | 4 | 954/970 | − 0.44 | − 0.68, − 0.19 | < 0.001 | 99 | 0.50, 1.48 |
FPG (mmol/l) | 4 | 954/970 | − 0.88 | − 1.20, − 0.55 | < 0.001 | 100 | 0.51, 1.49 |
PPG (mmol/l) | – | – | – | – | – | – | – |
Weight (kg) | 4 | 954/970 | 1.93 | 1.88, 1.97 | < 0.001 | 40 | − 0.09, 0.89 |
TZD + metformin vs. TZD | |||||||
HbA1c (%) | 2 | 356/348 | − 0.83 | − 0.97, − 0.68 | < 0.001 | 41 | – |
FPG (mmol/l) | 2 | 356/348 | − 1.25 | − 1.75, − 0.75 | < 0.001 | 99 | – |
PPG (mmol/l) | – | – | – | – | – | – | – |
Weight (kg) | 2 | 356/348 | − 1.22 | − 1.89, − 0.55 | < 0.001 | 76 | – |
SGLT2 inhibitors + metformin vs. metformin | |||||||
HbA1c (%) | 3 | 978/974 | − 0.47 | − 0.58, − 0.37 | < 0.001 | 98 | 0.30, 1.66 |
FPG (mmol/l) | 2 | 642/646 | − 1.38 | − 1.60, − 1.17 | < 0.001 | 99 | – |
PPG (mmol/l) | – | – | – | – | – | – | – |
Weight (kg) | 3 | 978/974 | − 2.00 | − 2.29, − 1.71 | < 0.001 | 98 | 0.30, 1.66 |
SGLT2 inhibitors + metformin vs, SGLT2 inhibitors | |||||||
HbA1c (%) | 3 | 978/989 | − 0.64 | − 0.84, − 0.43 | < 0.001 | 100 | 0.32, 1.68 |
FPG (mmol/l) | 2 | 642/646 | − 0.83 | − 1.05, − 0.61 | < 0.001 | 99 | – |
PPG (mmol/l) | – | – | – | – | – | – | – |
Weight (kg) | 3 | 978/989 | − 0.66 | − 1.06, − 0.27 | < 0.001 | 99 | 0.31, 1.67 |
DPP-4 inhibitors + TZD vs. TZD | |||||||
HbA1c (%) | 6 | 1577/1431 | − 0.54 | − 0.65, − 0.44 | < 0.001 | 99 | 0.70, 1.28 |
FPG (mmol/l) | 6 | 1577/1431 | − 0.89 | − 1.01, − 0.76 | < 0.001 | 97 | 0.68, 1.26 |
PPG (mmol/l) | 4 | 842/824 | − 1.97 | − 2.37, − 1.58 | < 0.001 | 97 | 0.48, 1.46 |
Weight (kg) | 6 | 1577/1431 | 0.96 | 0.79, 1.14 | < 0.001 | 96 | 0.67, 1.25 |
DPP-4 inhibitors + TZD vs. DPP-4 inhibitors | |||||||
HbA1c (%) | 3 | 502/504 | − 0.62 | − 0.75, − 0.48 | < 0.001 | 99 | 0.31, 1.67 |
I2 (mmol/l) | 3 | 502/504 | − 1.41 | − 1.50, − 1.31 | < 0.001 | 90 | 0.22, 1.58 |
PPG (mmol/l) | – | – | – | – | – | – | – |
Weight (kg) | 3 | 502/504 | 3.51 | 2.13, 4.88 | < 0.001 | 100 | 0.32, 1.68 |
Adverse Effects of Initial Combination Therapy
Comparison group | No. of patients | Relative risk | 95% CI | p value | I2 (%) | 95% CI of I2 |
---|---|---|---|---|---|---|
DPP-4 inhibitors + metformin vs. DPP-4 inhibitors | ||||||
AE | 1967/1951 | 1.07 | 0.94, 1.22 | 0.29 | 0 | − 0.24, 0.24 |
Drug-related AE | 1514/1489 | 1.73 | 1.39, 2.16 | < 0.001 | 2 | − 0.25, 0.29 |
Hypoglycemia | 1824/1823 | 1.84 | 1.19, 2.85 | 0.007 | 27 | 0.02, 0.52 |
GI adverse effects | 1584/1591 | 2.19 | 1.48, 3.23 | < 0.001 | 62 | 0.33, 0.91 |
SAE | 1742/1746 | 0.70 | 0.45, 1.08 | 0.11 | 42 | 0.15, 0.69 |
Discontinuation due to AE | 1584/1591 | 0.77 | 0.48, 1.24 | 0.29 | 12 | − 0.17, 0.41 |
DPP-4 inhibitors + metformin vs. metformin | ||||||
AE | 3379/3375 | 0.92 | 0.83, 1.01 | 0.09 | 0 | − 0.19, 0.19 |
Drug-related AE | 2926/2920 | 0.97 | 0.84, 1.11 | 0.63 | 0 | − 0.20, 0.20 |
Hypoglycemia | 3379/3375 | 1.15 | 0.84, 1.55 | 0.38 | 17 | − 0.02, 0.36 |
GI adverse effects | 2996/2989 | 0.91 | 0.80, 1.04 | 0.17 | 0 | − 0.21, 0.21 |
SAE | 3154/3150 | 0.71 | 0.50, 1.01 | 0.05 | 0 | − 0.20, 0.20 |
Discontinuation due to AE | 2996/2989 | 0.88 | 0.63, 1.22 | 0.44 | 0 | − 0.21, 0.21 |
SU/glinide + metformin vs.metformin | ||||||
AE | 425/429 | 1.26 | 0.90, 1.76 | 0.17 | 0 | − 0.68, 0.68 |
Hypoglycemia | 425/429 | 8.91 | 1.46, 54.34 | 0.02 | 76 | 0.08, 1.44 |
GI adverse effects | 425/429 | 0.70 | 0.48, 1.01 | 0.06 | 65 | − 0.03, 1.33 |
SAE | – | – | – | – | – | – |
Discontinuation due to AE | – | – | – | – | – | – |
SU/glinide + metformin vs. SU/glinide | ||||||
AE | 425/416 | 0.98 | 0.70, 1.37 | 0.92 | 0 | − 0.68, 0.68 |
Hypoglycemia | 425/416 | 0.63 | 0.48, 0.82 | < 0.001 | 93 | 0.25, 1.61 |
GI adverse effects | 425/416 | 1.42 | 1.08,1.88 | 0.01 | 25 | − 0.43, 0.93 |
SAE | – | – | – | – | – | – |
Discontinuation due to AE | – | – | – | – | – | – |
TZD + metformin vs.metformin | ||||||
AE | 954/970 | 1.06 | 0.88, 1.28 | 0.55 | 0 | − 0.49, 0.49 |
Hypoglycemia | 954/970 | 1.60 | 1.05, 2.46 | 0.03 | 0 | − 0.49, 0.49 |
GI adverse effects | 954/970 | 0.87 | 0.75, 1.01 | 0.07 | 0 | − 0.49, 0.49 |
SAE | 954/970 | 0.98 | 0.65, 1.47 | 0.91 | 0 | − 0.49, 0.49 |
Discontinuation due to AE | 954/970 | 1.06 | 0.72, 1.56 | 0.76 | 0 | − 0.49, 0.49 |
TZD + metformin vs. TZD | ||||||
AE | 356/348 | 1.31 | 0.97, 1.76 | 0.08 | 84 | – |
Hypoglycemia | 356/348 | 1.53 | 0.80, 2.91 | 0.20 | 0 | – |
GI adverse effects | – | – | – | – | – | – |
SAE | 356/348 | 0.87 | 0.32, 2.37 | 0.79 | 0 | – |
Discontinuation due to AE | – | – | – | – | – | – |
SGLT2 inhibitors + metformin vs. metformin | ||||||
AE | 978/974 | 1.19 | 0.99, 1.43 | 0.06 | 3 | − 0.37, 0.43 |
Drug-related AE | 978/974 | 1.45 | 1.12, 1.87 | 0.004 | 0 | − 0.40, 0.40 |
Hypoglycemia | 642/646 | 1.37 | 0.64, 2.92 | 0.42 | 17 | − 0.51, 0.85 |
GI adverse effects | 978/974 | 0.72 | 0.40, 1.07 | 0.25 | 73 | 0.33, 1.13 |
SAE | 978/974 | 0.84 | 0.43, 1.65 | 0.62 | 0 | − 0.49, 0.49 |
Discontinuation due to AE | 978/974 | 0.82 | 0.47, 1.41 | 0.46 | 0 | − 0.40, 0.40 |
SGLT2 inhibitors + metformin vs. SGLT2 inhibitors | ||||||
AE | 1220/1236 | 1.16 | 0.99, 1.37 | 0.07 | 52 | 0.12, 0.92 |
Drug-related AE | 1220/1236 | 1.13 | 0.90, 1.42 | 0.31 | 68 | 0.28, 1.08 |
Hypoglycemia | 642/646 | 2.23 | 1.13, 4.41 | 0.02 | 27 | − 0.41, 0.95 |
GI adverse effects | 978/989 | 1.99 | 1.39, 2.86 | 0.002 | 0 | − 0.40, 0.40 |
SAE | 978/989 | 0.62 | 0.33, 1.16 | 0.13 | 0 | − 0.40, 0.40 |
Discontinuation due to AE | 978/989 | 0.83 | 0.48, 1.43 | 0.50 | 0 | − 0.40, 0.40 |
DPP-4 inhibitors + TZD vs. TZD | ||||||
AE | 1154/1138 | 0.94 | 0.80, 1.12 | 0.50 | 0 | − 0.35, 0.35 |
Drug-related AE | 1265/1107 | 1.06 | 0.79, 1.41 | 0.70 | 0 | − 0.35, 0.35 |
Hypoglycemia | 1413/1268 | 1.08 | 0.77, 1.53 | 0.65 | 0 | − 0.31, 0.31 |
GI adverse effects | 1265/1107 | 0.86 | 0.56, 1.33 | 0.50 | 25 | − 0.10, 0.60 |
SAE | 1170/1140 | 1.31 | 0.85, .2.01 | 0.22 | 0 | − 0.35, 0.35 |
Discontinuation due to AE | 1006/977 | 0.80 | 0.47, 1.38 | 0.42 | 3 | − 0.37, 0.43 |
DPP-4 inhibitors + TZD vs. DPP-4 inhibitors | ||||||
AE | 502/504 | 1.09 | 0.85, 1.40 | 0.50 | 45 | − 0.68, 0.68 |
Drug-related AE | 350/354 | 1.40 | 0.92, 2.15 | 0.12 | 17 | – |
Hypoglycemia | 350/354 | 0.84 | 0.46, 1.53 | 0.57 | 0 | – |
GI adverse effects | – | – | – | – | – | – |
SAE | 350/354 | 1.31 | 0.66, 2.59 | 0.44 | 78 | – |
Discontinuation due to AE | – | – | – | – | – | – |